Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians

Conclusions Cumulative incidence of HCC is low in patients treated with ETV, but ETV does not eliminate the risk of HCC. Discriminatory performance of HCC risk scores was limited, particularly in Caucasians, at baseline and during therapy.

http://gut.bmj.com/cgi/content/short/64/8/1289?rss=1

Source: Gut - July 9, 2015 Category: Gastroenterology Authors: Arends, P., Sonneveld, M. J., Zoutendijk, R., Carey, I., Brown, A., Fasano, M., Mutimer, D., Deterding, K., Reijnders, J. G. P., Oo, Y., Petersen, J., van Bommel, F., de Knegt, R. J., Santantonio, T., Berg, T., Welzel, T. M., Wedemeyer, H., Buti, M., Prad Tags: Hepatitis B, Hepatic cancer Hepatology Source Type: research